Actively Recruiting
Prospective Registry Trial Comparing Stereotactic Body Radiotherapy (SBRT) to Conventional Palliative Radiotherapy (CRT) in Patients With Spinal Metastases
Led by University Health Network, Toronto · Updated on 2026-03-05
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are observing how radiation oncologists decide between stereotactic body radiotherapy (SBRT) and conventional radiotherapy (CRT) for patients with spinal metastases. This observational study aims to compare real-world outcomes such as local tumor progression, pain relief, and overall survival for these two radiation treatments. The study will help develop an evidence-based guide to support treatment decisions for spinal metastases in the future. Participants will receive either SBRT or CRT as part of their standard care according to institutional guidelines. Radiation oncologists will complete questionnaires to share their decision-making processes. The study collects data on treatment choice and patient outcomes over time without altering the care patients receive. During the study, patients will be monitored for local progression of their spinal tumors, changes in pain levels, adverse events, and overall survival for up to two years. Researchers will gather information through medical records and questionnaires to understand treatment effects and decision factors. Participation involves regular follow-up visits and assessments as part of routine care, with no experimental interventions being assigned.
CONDITIONS
Brief Title
Comparing SBRT to CRT in Patients With Spinal Metastases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years of age or older
- Patients with painful spinal metastases suitable for radiation treatment
- Confirmed prior histological cancer diagnosis
- Able to provide written consent
- ECOG performance status between 0 and 3
You will not qualify if you...
- Prior radiotherapy overlapping treatment area leading to excessive organ doses
- Diagnosis of lymphoma, myeloma, or germ cell malignancies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 years
Participants who undergo routine care radiotherapy are observed to assess treatment outcomes including local progression, pain response, adverse events, and overall survival.
Regular assessments during routine care visits
Trial Site Locations
Total: 1 location
1
University Health Network
Toronto, Ontario, Canada, M5G 1X6
Actively Recruiting
Research Team
D
David Shultz, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here